VIVUS, Inc. is a biopharmaceutical company. The Company operates in the development and commercialization of therapeutic products segment. It provides over two therapies approved by the Food and Drug Association (FDA), which include Qsymia (phentermine and topiramate extended-release) for chronic weight management and STENDRA (avanafil) for erectile dysfunction (ED). The Company has completed the Phase II studies of Qsymia for the indication of Obstructive Sleep Apnea (OSA) and diabetes. Its Qsymia is available in over 40,000 certified retail pharmacies across the country. Its STENDRA is also approved by the European Commission (EC), under the name, SPEDRA, for the treatment of ED in the Europe. The United States Food and Drug Association approved a Supplemental New Drug Application (sNDA) for STENDRA. STENDRA is indicated to be taken approximately 15 minutes before sexual activity.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biopharmaceuticals
- Sub-Industry: Pharmaceuticals
- Symbol: NASDAQ:VVUS
- CUSIP: 92855110
- Web: www.vivus.com
Capitalization:- Market Cap: $101.89 million
- Outstanding Shares: 105,812,000
Average Prices:- 50 Day Moving Avg: $0.98
- 200 Day Moving Avg: $1.09
- 52 Week Range: $0.86 - $1.47
P/E:- Trailing P/E Ratio: 3.113
- Foreward P/E Ratio: -2.14
- P/E Growth: -3.090
Sales & Book Value:- Annual Revenue: $133.4 million
- Price / Sales: 0.77
- Book Value: $0.05 per share
- Price / Book: 18.56
Profitability:- EBIDTA: $67.14 million
- Net Margins: 24.72%
- Return on Equity: 3,746.48%
- Return on Assets: 11.02%
Debt:- Debt-to-Equity Ratio: 40.25%
- Current Ratio: 5.51%
- Quick Ratio: 5.20%
Misc:- Average Volume: 896,919 shs.
- Beta: 0.88
- Short Ratio: 9.72
Frequently Asked Questions for VIVUS (NASDAQ:VVUS)
What is VIVUS's stock symbol?
VIVUS trades on the NASDAQ under the ticker symbol "VVUS."
How were VIVUS's earnings last quarter?
VIVUS, Inc. (NASDAQ:VVUS) issued its earnings results on Thursday, August, 4th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.31) by $0.20. The business earned $13.77 million during the quarter, compared to analysts' expectations of $19 million. VIVUS had a net margin of 24.72% and a return on equity of 3,746.48%. The business's revenue for the quarter was down 40.1% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.19) earnings per share. View VIVUS's Earnings History.
When will VIVUS make its next earnings announcement?
Are investors shorting VIVUS?
VIVUS saw a decline in short interest in August. As of August 31st, there was short interest totalling 5,103,560 shares, a decline of 28.0% from the August 15th total of 7,085,696 shares. Based on an average daily volume of 1,100,513 shares, the short-interest ratio is presently 4.6 days. Approximately 5.1% of the company's stock are sold short.
Who are some of VIVUS's key competitors?
Some companies that are related to VIVUS include Kadmon Holdings (KDMN), Kamada (KMDA), Vericel Corporation (VCEL), Peregrine Pharmaceuticals (PPHM), MediWound (MDWD), Alimera Sciences (ALIM), Opiant Pharmaceuticals (OPNT), Cardiome Pharma Corporation (CRME), KalVista Pharmaceuticals (KALV), Chiasma (CHMA), Cesca Therapeutics (KOOL), Tokai Pharmaceuticals (NVUS), Ocera Therapeutics (OCRX), Sonoma Pharmaceuticals (SNOA), Catalyst Biosciences (CBIO), Onconova Therapeutics (ONTX), Argos Therapeutics (ARGS) and Auxilium Pharmaceuticals (AUXL).
Who are VIVUS's key executives?
VIVUS's management team includes the folowing people:
- David York Norton, Chairman of the Board and Director
- Seth H. Z. Fischer, Chief Executive Officer, Chief Commercial Officer, Director
- Mark K. Oki CPA, Chief Financial Officer, Chief Accounting Officer
- John L. Slebir Esq., Senior Vice President - Business Development, General Counsel, Secretary
- Guy P. Marsh, Vice President - U.S. Operations, General Manager
- Johann Noor Mohamed, Vice President, Corporate Controller
- Wesley W. Day Ph.D., Vice President - Clinical Development
- Santosh T. Varghese M.D, Vice President-Medical & Regulatory Affairs, Pharmacovigilance, and QA
- Thomas B. King, Director
- Herman Rosenman CPA, Director
Who owns VIVUS stock?
VIVUS's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include North Tide Capital LLC (4.73%), Vanguard Group Inc. (3.09%), AJO LP (2.58%), Acadian Asset Management LLC (1.74%), OxFORD Asset Management LLP (0.88%) and Menta Capital LLC (0.27%). Company insiders that own VIVUS stock include John L Slebir, North Tide Capital, Llc and Santosh T Varghese. View Institutional Ownership Trends for VIVUS.
Who sold VIVUS stock? Who is selling VIVUS stock?
VIVUS's stock was sold by a variety of institutional investors in the last quarter, including North Tide Capital LLC, Vanguard Group Inc., Nine Chapters Capital Management LLC, Menta Capital LLC, Royal Bank of Canada and State Street Corp. Company insiders that have sold VIVUS stock in the last year include North Tide Capital, Llc and Santosh T Varghese. View Insider Buying and Selling for VIVUS.
Who bought VIVUS stock? Who is buying VIVUS stock?
VIVUS's stock was bought by a variety of institutional investors in the last quarter, including AJO LP, Acadian Asset Management LLC, OxFORD Asset Management LLP, Spark Investment Management LLC, Russell Investments Group Ltd., Northern Trust Corp, Bank of New York Mellon Corp and IHT Wealth Management LLC. View Insider Buying and Selling for VIVUS.
How do I buy VIVUS stock?
Shares of VIVUS can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is VIVUS's stock price today?
One share of VIVUS stock can currently be purchased for approximately $0.97.
MarketBeat Community Rating for VIVUS (NASDAQ VVUS)MarketBeat's community ratings are surveys of what our community members think about VIVUS and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Earnings History for VIVUS (NASDAQ:VVUS)Earnings History by Quarter for VIVUS (NASDAQ VVUS)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/7/2017 | | ($0.13) | | | | | N/A |  |
| 5/3/2017 | Q1 2017 | ($0.13) | ($0.01) | | $27.01 million | View | Listen | |
| 3/8/2017 | Q4 2016 | $0.23 | $0.54 | $48.82 million | $81.81 million | View | Listen | |
| 11/9/2016 | Q316 | ($0.19) | ($0.09) | $21.91 million | $13.40 million | View | Listen | |
| 8/4/2016 | Q216 | ($0.31) | ($0.11) | $19.00 million | $13.77 million | View | N/A | |
| 5/3/2016 | Q116 | ($0.21) | ($0.12) | $17.97 million | $15.32 million | View | N/A | |
| 3/9/2016 | Q4 | ($0.12) | ($0.12) | $22.90 million | $15.34 million | View | N/A | |
| 11/4/2015 | Q315 | ($0.17) | ($0.15) | $20.24 million | $24.90 million | View | N/A | |
| 7/30/2015 | Q215 | ($0.23) | ($0.19) | $18.76 million | $23.00 million | View | Listen | |
| 5/5/2015 | Q115 | ($0.22) | ($0.15) | $21.80 million | $32.20 million | View | N/A | |
| 2/24/2015 | Q414 | ($0.25) | ($0.25) | $20.00 million | $21.70 million | View | Listen | |
| 11/5/2014 | Q314 | ($0.25) | ($0.10) | $21.90 million | $33.90 million | View | Listen | |
| 8/7/2014 | Q214 | ($0.28) | ($0.25) | $17.90 million | $21.90 million | View | Listen | |
| 5/5/2014 | Q114 | ($0.37) | ($0.15) | $11.40 million | $36.70 million | View | N/A | |
| 2/24/2014 | Q413 | ($0.40) | ($0.17) | $28.20 million | $44.06 million | View | Listen | |
| 11/5/2013 | Q313 | ($0.38) | ($0.48) | $21.78 million | $27.38 million | View | N/A | |
| 8/6/2013 | Q2 2013 | ($0.44) | ($0.55) | $12.76 million | $5.53 million | View | N/A | |
| 5/8/2013 | Q1 2013 | ($0.51) | ($0.53) | $5.22 million | $4.10 million | View | N/A | |
| 2/25/2013 | Q4 2012 | ($0.44) | ($0.56) | $3.09 million | $1.97 million | View | N/A | |
| 11/6/2012 | Q312 | ($0.34) | ($0.40) | $0.35 million | $0.04 million | View | N/A | |
| 8/7/2012 | | ($0.23) | ($0.24) | | | View | N/A | |
| 5/7/2012 | | ($0.13) | ($0.20) | | | View | N/A | |
| 2/28/2012 | | ($0.12) | ($0.14) | | | View | N/A | |
| 11/7/2011 | | ($0.12) | ($0.10) | | | View | N/A | |
| 8/1/2011 | | ($0.13) | ($0.20) | | | View | N/A | |
| 5/2/2011 | | ($0.15) | ($0.12) | | | View | N/A | |
| 2/28/2011 | | ($0.22) | ($0.23) | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for VIVUS (NASDAQ:VVUS)Current Year EPS Consensus Estimate: $-0.39 EPS
Next Year EPS Consensus Estimate: $-0.45 EPS
Dividend History for VIVUS (NASDAQ:VVUS)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for VIVUS (NASDAQ:VVUS)Insider Ownership Percentage: 3.00%
Institutional Ownership Percentage: 35.82%
Insider Trades by Quarter for VIVUS (NASDAQ:VVUS)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 7/3/2017 | Santosh T Varghese | Insider | Sell | 423 | $1.23 | $520.29 | |
| 4/4/2017 | Santosh T Varghese | Insider | Sell | 440 | $1.08 | $475.20 | |
| 3/10/2017 | North Tide Capital, Llc | Major Shareholder | Sell | 1,149,400 | $1.16 | $1,333,304.00 | |
| 3/7/2017 | North Tide Capital, Llc | Major Shareholder | Sell | 192,800 | $1.08 | $208,224.00 | |
| 3/2/2017 | North Tide Capital, Llc | Major Shareholder | Sell | 160,100 | $1.13 | $180,913.00 | |
| 2/27/2017 | North Tide Capital, Llc | Major Shareholder | Sell | 333,000 | $1.14 | $379,620.00 | |
| 2/22/2017 | North Tide Capital, Llc | Major Shareholder | Sell | 161,800 | $1.11 | $179,598.00 | |
| 2/16/2017 | North Tide Capital, Llc | Major Shareholder | Sell | 305,090 | $1.10 | $335,599.00 | |
| 2/13/2017 | North Tide Capital, Llc | Major Shareholder | Sell | 176,410 | $1.11 | $195,815.10 | |
| 2/8/2017 | North Tide Capital, Llc | Major Shareholder | Sell | 563,527 | $1.06 | $597,338.62 | |
| 2/7/2017 | North Tide Capital, Llc | Major Shareholder | Sell | 6,200 | $1.11 | $6,882.00 | |
| 2/6/2017 | North Tide Capital, Llc | Major Shareholder | Sell | 28,027 | $1.10 | $30,829.70 | |
| 2/3/2017 | North Tide Capital, Llc | Major Shareholder | Sell | 78,633 | $1.12 | $88,068.96 | |
| 1/28/2017 | Santosh T Varghese | Insider | Sell | 429 | $1.11 | $476.19 | |
| 12/31/2016 | Santosh T Varghese | Insider | Sell | 13,790 | $1.12 | $15,444.80 | |
| 10/1/2016 | Santosh T Varghese | Insider | Sell | 710 | $1.14 | $809.40 | |
| 8/2/2016 | Santosh T Varghese | Insider | Sell | 12,559 | $1.07 | $13,438.13 | |
| 7/1/2016 | Santosh T Varghese | VP | Sell | 366 | $1.21 | $442.86 | |
| 4/7/2016 | Santosh T Varghese | Insider | Sell | 329 | $1.65 | $542.85 | |
| 4/1/2016 | North Tide Capital, Llc | Major Shareholder | Buy | 2,160 | $1.40 | $3,024.00 | |
| 3/31/2016 | North Tide Capital, Llc | Major Shareholder | Buy | 383,300 | $1.29 | $494,457.00 | |
| 3/28/2016 | North Tide Capital, Llc | Major Shareholder | Buy | 202,000 | $1.12 | $226,240.00 | |
| 3/16/2016 | North Tide Capital, Llc | Major Shareholder | Buy | 500,000 | $1.21 | $605,000.00 | |
| 1/1/2016 | John L Slebir | SVP | Sell | 2,973 | $3.04 | $9,037.92 | |
| 1/8/2015 | North Tide Capital, Llc | Major Shareholder | Buy | 500,000 | $3.12 | $1,560,000.00 | |
| 1/6/2015 | North Tide Capital, Llc | Major Shareholder | Buy | 476,800 | $3.04 | $1,449,472.00 | |
| 1/2/2015 | North Tide Capital, Llc | Major Shareholder | Buy | 523,200 | $2.90 | $1,517,280.00 | |
| 3/11/2014 | Seth H.Z. Fischer | CEO | Buy | 3,080 | $6.07 | $18,695.60 | |
| 11/11/2013 | Alexander Denner | Director | Buy | 566,844 | $8.59 | $4,869,189.96 | |
| 9/5/2013 | Timothy E Morris | CFO | Sell | 10,654 | $11.95 | $127,315.30 | |
| 9/4/2013 | Michael J Astrue | Director | Buy | 10,000 | $11.96 | $119,600.00 | |
| 6/27/2013 | Jon C Biro | Insider | Buy | 2,000 | $12.85 | $25,700.00 | |
| 5/29/2013 | Ernest Mario | Director | Buy | 15,000 | $14.68 | $220,200.00 | |
| 8/20/2012 | Ernest Mario | Director | Buy | 5,000 | $20.75 | $103,750.00 | |
| 8/10/2012 | Ernest Mario | Director | Buy | 20,000 | $21.74 | $434,800.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for VIVUS (NASDAQ:VVUS)
Latest Headlines for VIVUS (NASDAQ:VVUS)
| Source: |
|
| Date | Headline |
|---|
 | Zacks: Analysts Expect VIVUS, Inc. (VVUS) Will Post Earnings of -$0.13 Per Share
www.americanbankingnews.com - September 20 at 4:12 PM |
| Critical Survey: VIVUS (VVUS) versus Its Rivals
www.americanbankingnews.com - September 18 at 2:26 AM |
| VIVUS, Inc. (VVUS) Sees Large Drop in Short Interest
www.americanbankingnews.com - September 15 at 1:28 AM |
 | VIVUS (VVUS) Says Tacrolimus Received Orphan Drug Designation in the European Union for the Treatment of PAH
www.streetinsider.com - September 8 at 10:10 AM |
 | VIVUS, Aggressive Marketing For Approved Drugs, Milestone for Tacrolimus, Pipeline Analysis
finance.yahoo.com - September 8 at 10:10 AM |
| VIVUS Announces Tacrolimus Receives Orphan Drug Designation in the European Union for the Treatment of Pulmonary Arterial Hypertension
finance.yahoo.com - September 7 at 11:05 AM |
| VIVUS (VVUS), Alvogen Announce Marketing Agreement for Qsymia in Republic of Korea - StreetInsider.com
www.streetinsider.com - September 6 at 10:09 AM |
| VIVUS and Alvogen Announce Marketing Agreement for Qsymia(R) in the Republic of Korea
finance.yahoo.com - September 6 at 10:09 AM |
| VIVUS (VVUS) Down 19.8% Since Earnings Report: Can It Rebound?
finance.yahoo.com - September 4 at 3:41 PM |
| VIVUS (VVUS) and Alimera Sciences (ALIM) Head to Head Survey
www.americanbankingnews.com - September 2 at 10:24 PM |
| VIVUS, Inc. (VVUS) Expected to Announce Earnings of -$0.13 Per Share
www.americanbankingnews.com - September 2 at 2:26 AM |
| VIVUS, Inc. (VVUS) Downgraded by ValuEngine
www.americanbankingnews.com - September 2 at 12:06 AM |
| VIVUS (VVUS) Settles with Dr. Reddy's Laboratories on Qsymia ... - StreetInsider.com
www.streetinsider.com - August 31 at 1:57 AM |
| VIVUS Announces Settlement with Dr. Reddy's Laboratories on Qsymia(R) Patent Litigation
finance.yahoo.com - August 30 at 8:54 PM |
 | Vivid Potential Victory With Vivus, Inc. Convertible Bonds - Seeking Alpha
seekingalpha.com - August 23 at 1:46 PM |
| VIVUS to Present at 2017 Wells Fargo Healthcare Conference on September 7, 2017
finance.yahoo.com - August 23 at 1:46 PM |
| Critical Review: VIVUS (VVUS) & Tokai Pharmaceuticals (NVUS)
www.americanbankingnews.com - August 19 at 8:44 AM |
| Zacks: Brokerages Expect VIVUS, Inc. (NASDAQ:VVUS) to Post -$0.13 Earnings Per Share
www.americanbankingnews.com - August 14 at 2:30 PM |
| Vivus Pipeline Review, Analysis and Potential Catalysts
finance.yahoo.com - August 10 at 9:34 AM |
 | VIVUS (VVUS) Q2 Loss In Line with Estimates, Sales Down Y/Y - Nasdaq
www.nasdaq.com - August 9 at 8:59 AM |
| VIVUS (VVUS) Q2 Loss In Line with Estimates, Sales Down Y/Y
finance.yahoo.com - August 8 at 8:15 AM |
| Peregrine Pharmaceuticals (PPHM) & VIVUS (VVUS) Head-To-Head Analysis
www.americanbankingnews.com - August 5 at 8:36 PM |
 | VIVUS Reports Second Quarter 2017 Financial Results
feeds.benzinga.com - August 3 at 4:34 PM |
| -$0.13 EPS Expected for VIVUS, Inc. (NASDAQ:VVUS) This Quarter
www.americanbankingnews.com - July 27 at 11:17 AM |
| Zacks Investment Research Upgrades VIVUS, Inc. (VVUS) to "Buy"
www.americanbankingnews.com - July 27 at 10:14 AM |
| VIVUS, Inc. (NASDAQ:VVUS) Set to Announce Earnings on Wednesday
www.americanbankingnews.com - July 26 at 7:48 AM |
| VIVUS, Inc. (VVUS) Cut to "Hold" at Zacks Investment Research
www.americanbankingnews.com - July 19 at 12:38 PM |
| VIVUS, Inc. (VVUS) Raised to "Buy" at Zacks Investment Research
www.americanbankingnews.com - July 17 at 2:52 PM |
| VIVUS Announces Settlement with Actavis on Qsymia(R) Patent Litigation
finance.yahoo.com - July 6 at 5:16 PM |
| VIVUS, Inc. (NASDAQ:VVUS) Downgraded to "Hold" at Zacks Investment Research
www.americanbankingnews.com - July 4 at 1:07 PM |
| VIVUS, Inc. (NASDAQ:VVUS) Expected to Announce Earnings of -$0.13 Per Share
www.americanbankingnews.com - July 3 at 10:14 AM |
| Shire's (SHPG) ADHD Drug Mydayis Receives Approval in US
finance.yahoo.com - June 22 at 2:38 PM |
| Myriad Genetics (MYGN) Catches Eye: Stock Moves Up 5.7%
finance.yahoo.com - June 22 at 2:38 PM |
| Fibrocell Science (FCSC) Looks Good: Stock Moves Up 13.9%
finance.yahoo.com - June 20 at 9:09 AM |
| Interpace Diagnostics Group, Inc. (IDXG)
finance.yahoo.com - June 17 at 7:13 AM |
| Celgene (CELG) Reports Data on Lupus Drug in Phase II Trial
finance.yahoo.com - June 15 at 8:56 PM |
| Novartis Presents Positive Data on CAR-T Cell Therapy Drug
finance.yahoo.com - June 12 at 8:04 PM |
| VIVUS (VVUS) Shares March Higher, Can It Continue?
finance.yahoo.com - June 8 at 1:57 AM |
| Zacks: Brokerages Expect VIVUS, Inc. (VVUS) Will Post Earnings of -$0.13 Per Share
www.americanbankingnews.com - June 7 at 8:06 AM |
| Perrigo's (PRGO) Q1 Earnings Beat Estimates, Guidance Intact
finance.yahoo.com - May 31 at 11:39 AM |
| ETFs with exposure to VIVUS, Inc. : May 30, 2017
finance.yahoo.com - May 30 at 8:08 PM |
| Intercept's (ICPT) Liver Drug Ocaliva Approved in Canada
finance.yahoo.com - May 29 at 3:33 PM |
| VIVUS, Inc. :VVUS-US: Earnings Analysis: Q1, 2017 By the Numbers : May 26, 2017
finance.yahoo.com - May 28 at 10:51 PM |
| VIVUS (VVUS) Names Thomas King to Board of Directors - StreetInsider.com
www.streetinsider.com - May 26 at 8:31 AM |
 | 5 Reasons Why VIVUS, Inc. (VVUS) Stock Should Be in Your Portfolio - Investorplace.com
investorplace.com - May 26 at 8:31 AM |
| 5 Reasons Why VIVUS, Inc. (VVUS) Stock Should Be in Your Portfolio
investorplace.com - May 25 at 7:48 AM |
| Thomas B. King Joins VIVUS' Board of Directors
finance.yahoo.com - May 25 at 7:16 AM |
| Astrazeneca (AZN) Gets Positive CHMP Opinion for Brodalumab
finance.yahoo.com - May 22 at 7:38 PM |
| Shire (SHPG) Up on Positive Phase III Study Data on HAE Drug
finance.yahoo.com - May 19 at 6:44 PM |
| Zacks: Analysts Anticipate VIVUS, Inc. (VVUS) Will Post Earnings of -$0.13 Per Share
www.americanbankingnews.com - May 11 at 9:07 AM |
VIVUS (VVUS) Chart for Monday, September, 25, 2017
